Latest Breaking News On - European union summary of product characteristics - Page 1 : comparemela.com

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating

United statesUnited kingdomSwitzerland generalShabir hashamDario eklundAndrew smithEva kaliasChiesi farmaceuticiAmerica to catalyst pharmaceuticals incLife science allianceNational institute for healthSanthera pharmaceuticals holdingCatalyst pharmaceuticals incExchange regulation ltdRegulatory agencySanthera pharmaceuticals holding ltd

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomSwitzerland generalUnited statesDennis riedlEva kaliasDario eklundShabir hashamChiesi farmaceuticiAndrew smithSanthera pharmaceuticalsChina national medical products administrationCatalyst pharmaceuticalsHead investor relations communicationsExchange regulationEuropean medicines agencyEuropean union summary of product characteristics

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China s NMPA -March 27, 2024 at 02:01 am EDT

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China s NMPA -March 27, 2024 at 02:01 am EDT
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalUnited kingdomUnited statesNorth lanarkshireEva kaliasAmerica to catalyst pharmaceuticals incSanthera pharmaceuticals holdingDrug administrationRegulatory agencyBreakthrough therapy programSanthera pharmaceuticalsEuropean union summary of product characteristicsChina national medical products administrationGlobenewswire incEuropean medicines agencyLife science alliance

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China s NMPA

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China s NMPA
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

North lanarkshireUnited kingdomSwitzerland generalUnited statesEva kaliasSanthera pharmaceuticals holdingChina national medical products administrationRegulatory agencySanthera pharmaceuticalsAmerica to catalyst pharmaceuticals incEuropean union summary of product characteristicsBreakthrough therapy programHead investor relations communicationsDrug administrationLife science allianceEuropean medicines agency

Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology

Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalUnited statesUnited kingdomEva kaliasDrug administrationSanthera pharmaceuticalsRegulatory agencyLife science allianceEuropean union summary of product characteristicsHead investor relations communicationsAmerica to catalyst pharmaceuticalsEuropean unionEuropean medicines agencySanthera pharmaceuticals holdingAnnounces publicationTolerability data